UNION has entered into a strategic veterinary partnership with Ceva Santé Animale S.A. (Ceva) on the candidate UNI83601. Ceva is developing UNION’s out-licensed UNI83601 for the treatment of canine pyoderma – one of the most frequent diseases in companion animals and a significant burden for animal patients and their owners.

For more information: www.ceva.com

For related press releases, please see:

Substantial psychosocial impacts of living with psoriasis 

The burden of living with psoriasis is often underestimated. In addition to the direct clinical challenges of psoriasis, many patients with plaque psoriasis suffer substantial psychosocial impacts from their disease, including: social stigma, feelings of rejection and shame, guilt, impaired sexual intimacy, discrimination in the workplace, difficulty finding employment or working outside the home, financial hardships, increased work absenteeism and reduced productivity. 


Treatment of psoriasis 

Psoriasis can be managed by topical, oral, biological treatments as well as phototherapy. Depending on the severity of the disease, patients and health care professionals choose between these treatment options. However, many physicians and patients express a need for better oral treatments. UNION is developing oral orismilast, a next-generation phosphodiesterase type-4 (“PDE4”) inhibitor, for the treatment of psoriasis. Read more here